Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Home

aurobindo pharma news

Tag: aurobindo pharma news

Read all Latest developments, information and news on and about Aurobindo Pharmaceuticals - Page 11

Aurobindo Pharma is a pharmaceutical manufacturing company headquartered in Hyderabad manufacturing generic pharmaceuticals and active pharmaceutical ingredients. - Latest Updates

USFDA issues 6 observations after inspection of Aurobindo Pharma's Jedcherla facility

Ruchika Sharma11 May 2022 12:59 PM IST

"The Company will respond to the USFDA within the stipulated timeline and work closely with USFDA to close the observations," the company added.

Sun Pharma, Aurobindo, Jubilant recall products in US

Ruchika Sharma25 April 2022 11:48 AM IST

The USFDA has classified the recalls as Class III, which is initiated in a " situation in which use of, or exposure to, a violative product is not...

Aurobindo Pharma acquires domestic formulation business of Veritaz for Rs 171 crore

Ruchika Sharma29 March 2022 11:47 AM IST

New Delhi: Drugmaker, Aurobindo Pharma, has recently announced the acquisition of domestic formulation business of Veritaz on a slump sale...

Sun Pharma, Aurobindo recall products in US over defaulting norms

MD Bureau28 Feb 2022 1:18 PM IST

New Delhi: Leading homegrown drug makers Aurobindo Pharma and Sun Pharmaceutical Industries are recalling different products in the US market due to...

Aurobindo Pharma net profit down 22 percent to Rs 604 crore in Q3

Ruchika Sharma10 Feb 2022 10:00 AM IST

New Delhi: Aurobindo Pharma on Wednesday said its consolidated net profit declined by 22.3 per cent to Rs 604.29 crore for the third quarter ended...

Aurobindo Pharma in trouble for manufacturing lapses at API plant

Ruchika Sharma28 Jan 2022 10:00 AM IST

The USFDA pointed at failure of the company's quality unit to ensure that critical deviations are investigated and resolved.

Aurobindo Pharma shares fall after USFDA warning letter

Dr. Divya Colin17 Jan 2022 9:00 AM IST

New Delhi: Shares of Aurobindo Pharma on Friday dipped over 3 per cent after the company said it has received a warning letter from the US health...

Aurobindo Pharma gets USFDA warning letter for Hyderabad facility over poor manufacturing practices

Ruchika Sharma14 Jan 2022 4:03 PM IST

New Delhi: Drugmaker, Aurobindo Pharma has announced that the company has received a warning letter from the US Food and Drug Administration...

Aurobindo arm, Orion expand licensing deal to commercialize biosimilars pipeline in select European markets

Ruchika Sharma12 Jan 2022 1:18 PM IST

Hyderabad: Aurobindo Pharma Limited (along with its subsidiaries together referred to as "Aurobindo") has announced that its subsidiary CuraTeQ...

Aurobindo Pharma launches COVID-19 drug Molnupiravir

Medical Dialogues Bureau7 Jan 2022 9:00 AM IST

HYDERABAD: Aurobindo Pharma Limited has launched COVID-19 treatment drug Molnupiravir under brand name "Molnaflu" in India.Molnupiravir is for...

Aurobindo Pharma appoints K Nithyananda Reddy as Managing Director

Ruchika Sharma1 Jan 2022 12:00 PM IST

Hyderabad: Aurobindo Pharma has recently announced the appointment of Mr. K. Nithyananda Reddy as the Managing Director while continuing as the...

Aurobindo Pharma gets USFDA OAI status for API facility in Hyderabad

Ruchika Sharma12 Nov 2021 2:33 PM IST

Hyderabad: Drugmaker, Aurobindo Pharma, has recently announced that the company has received Official Action Indicated (OAI) status...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok